Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theralase Technologies ( (TSE:TLT) ) has provided an update.
Theralase Technologies reported that its X-ray-activated Rutherrin compound achieved a 100% complete response and cancer-free survival in all animals treated in a preclinical orthotopic model of muscle invasive bladder cancer, outperforming both radiation-only and untreated control groups. The robust Kaplan–Meier survival data, highlighting durable benefit in an aggressive cancer setting, strengthens the case for Rutherrin as a potential bladder-sparing option versus current standards of care and underpins the company’s plan to advance into an adaptive Phase 0/I/II clinical trial in muscle invasive bladder cancer, pending toxicology and regulatory clearances.
The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TLT Stock
According to Spark, TipRanks’ AI Analyst, TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical-stage pharmaceutical company focused on developing energy-activated small molecules designed to safely and effectively destroy cancer, bacteria and viruses. The Toronto-based firm is advancing a pipeline led by its Rutherrin platform, targeting difficult-to-treat indications such as muscle invasive bladder cancer with novel, radiation-activated therapies.
Average Trading Volume: 140,222
Technical Sentiment Signal: Buy
Current Market Cap: C$73.26M
Learn more about TLT stock on TipRanks’ Stock Analysis page.